What PDS Biotechnology Corp's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 0 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Glover Steve C | Director | Feb 28 | Open-market buy · P | +15,061 | $1.66 | +$25K | 78,851 |
| Freitag Gregory Gene | Director | Feb 28 | Open-market buy · P | +15,060 | $1.66 | +$25K | 61,213 |
| Bedu-addo Frank | President/CEO | Dec 02 | Withheld — tax / exercise cost · F | −175,184 | $9.78 | −$1.71M | 690,866 |
| Bedu-addo Frank | President/CEO | Dec 02 | Exercise / conversion · M | +219,535 | $6.57 | +$1.44M | 866,050 |
| Hill Mathew C | Chief Financial Officer | Dec 13 | Open-market buy · P | +100 | $9.00 | +$900 | 4,075 |
| Hill Mathew C | Chief Financial Officer | Dec 13 | Open-market buy · P | +100 | $9.00 | +$900 | 3,975 |
| Hill Mathew C | Chief Financial Officer | Dec 13 | Open-market buy · P | +400 | $8.90 | +$3.56K | 3,875 |
| Hill Mathew C | Chief Financial Officer | Dec 13 | Open-market buy · P | +2,500 | $9.00 | +$22.5K | 3,475 |
| Bloomquist DeLyle W | Insider | Jun 16 | Open-market buy · P | +10,000 | $9.88 | +$98.8K | 193,888 |
| Bloomquist DeLyle W | Insider | Jun 16 | Exercise / conversion · M | +2,970 | $5.99 | +$17.8K | 183,888 |
| Ali-Jackson Kamil | Director | Jun 15 | Open-market buy · P | +11,764 | $8.50 | +$100K | 11,764 |
| Van Voorhees Seth | Chief Financial Officer | Jun 15 | Open-market buy · P | +17,647 | $8.50 | +$150K | 17,647 |
| Glover Steve C | Director | Jun 15 | Open-market buy · P | +5,882 | $8.50 | +$50K | 63,790 |
| Bedu-addo Frank | President/CEO | Jun 15 | Withheld — tax / exercise cost · F | −27,166 | $12.86 | −$349K | 646,515 |
| Bedu-addo Frank | President/CEO | Jun 15 | Exercise / conversion · M | +53,174 | $6.57 | +$349K | 673,681 |
| Freitag Gregory Gene | Director | Jun 15 | Open-market buy · P | +5,882 | $8.50 | +$50K | 46,153 |
| Saik Andrew | Chief Financial Officer | Feb 14 | Grant / award · A | +38,400 | $1.30 | +$49.9K | 42,549 |
| Glover Steve C | Director | Feb 14 | Grant / award · A | +38,400 | $1.30 | +$49.9K | 57,908 |
| Sykes Richard | Director | Feb 14 | Grant / award · A | +384,615 | $1.30 | +$500K | 445,108 |
| Freitag Gregory Gene | Director | Feb 14 | Grant / award · A | +38,400 | $1.30 | +$49.9K | 40,271 |
Loading...